DRUG · Unmapped registry intervention
Empagliflozin / Metformin HCl XR Tablets
Find medicine records ·
Find other trials using this name
Clinical trial
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
NCT07266766
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedBioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Type 2 Diabetes Mellitus (T2DM)unresolved
Interventions
Sponsors & collaborators
Humanis Saglık Anonim Sirketilead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07266766 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.